公司概述
Artelo Biosciences, Inc. operates as a clinical stage biopharmaceutical entity dedicated to the development and commercialization of therapeutics that target lipid-signaling pathways within the United States market. The company's strategic focus is anchored in its product candidate pipeline, which notably includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist designed to address specific biological targets. This biotechnology firm functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, where operational capital is primarily allocated toward advancing clinical research and regulatory submissions rather than immediate mass production. As of the latest reporting period, Artelo Biosciences, Inc. maintains a market capitalization of $5.32 million and employs a workforce of 7 individuals, reflecting a highly specialized and lean organizational structure typical of early-stage biopharmaceutical ventures. The combination of a sub-$10 million market cap and negligible revenue indicates that the company is currently in a pre-revenue or revenue-generation phase, where valuation is derived almost exclusively from potential future commercial milestones rather than current cash flows or profitability.
财务健康
The company's financial performance over the trailing twelve months (TTM) reveals a net income of $-12,879,000, while both revenue and EBITDA figures are not available for disclosure. The substantial gap between reported net income and the absence of revenue data underscores a cost structure heavily weighted toward research and development expenses, which are standard for clinical stage entities but result in significant operating losses at this stage. Free cash flow stands at $-4,168,625, indicating that the company is burning cash to fund its operations and pipeline advancement, thereby limiting immediate financial flexibility for external expansion without additional capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that mathematically reflects the absence of revenue and the inability to generate a profit on sales during the development phase. Regarding liquidity and leverage, the company holds $600,000 in cash against $678,000 in total debt, creating a position where cash reserves are slightly lower than total liabilities. The debt-to-equity ratio is listed as N/A, suggesting that traditional leverage metrics are distorted by the company's capital structure or negative equity, while the current ratio of 0.17 signals severe short-term liquidity constraints, as current assets are less than one-fifth of current liabilities. Return on Equity is reported at -1625.1% and Return on Assets at -190.1%, metrics that reveal management is currently utilizing shareholder capital and assets to generate substantial negative returns due to the intense capital expenditure required for drug development.
估值评估
Valuation multiples for Artelo Biosciences, Inc. present a complex picture, with a trailing twelve-month (TTM) P/E ratio listed as N/A due to the lack of positive earnings, and a forward P/E ratio of -7.40 that implies expectations of future losses or a negative earnings trajectory in the near term. The price-to-book ratio is reported at -3.44, a negative figure that indicates the market capitalization is below the company's book value, often seen in distressed or heavily loss-making biotechnology firms. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also N/A, suggesting that traditional revenue-based or earnings-based valuation models are not applicable given the current lack of sales and EBITDA data. In terms of price volatility, the stock has traded between a 52-week low of $2.96 and a 52-week high of $85.80, placing the current valuation context within a wide historical range that reflects high investor sentiment volatility. The beta value of 0.41 indicates that the stock's price movements are significantly less volatile than the broader market, suggesting a lower sensitivity to general market fluctuations despite the company's high-risk operational profile.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient revenue to calculate meaningful growth rates. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue, as both components of the growth equation are currently absent from the financial statements. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which is typical for biotechnology companies that reinvest all available resources into R&D and clinical trials rather than returning capital to shareholders. The overall growth and income profile of Artelo Biosciences, Inc. is characterized by a total reliance on external financing to sustain operations, with no current contribution to shareholder wealth through dividends or earnings growth, effectively prioritizing long-term asset accumulation and pipeline development over immediate financial returns.